STAAR/$STAA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About STAAR
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Ticker
$STAA
Sector
Primary listing
Employees
1,157
Headquarters
Website
STAAR Metrics
BasicAdvanced
$1.3B
-
-$1.93
0.62
-
Price and volume
Market cap
$1.3B
Beta
0.62
52-week high
$34.00
52-week low
$13.50
Average daily volume
718K
Financial strength
Current ratio
4.943
Quick ratio
3.832
Long term debt to equity
10.523
Total debt to equity
12.039
Profitability
EBITDA (TTM)
-72.989
Gross margin (TTM)
71.70%
Net profit margin (TTM)
-42.45%
Operating margin (TTM)
-36.28%
Effective tax rate (TTM)
2.36%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
-10.71%
Return on equity (TTM)
-25.55%
Valuation
Price to revenue (TTM)
5.965
Price to book
3.97
Price to tangible book (TTM)
4.29
Price to free cash flow (TTM)
-30.609
Free cash flow yield (TTM)
-3.27%
Free cash flow per share (TTM)
-0.887
Growth
Revenue change (TTM)
-32.59%
Earnings per share change (TTM)
-685.67%
3-year revenue growth (CAGR)
-4.98%
10-year revenue growth (CAGR)
12.02%
3-year earnings per share growth (CAGR)
40.97%
10-year earnings per share growth (CAGR)
23.26%
What the Analysts think about STAAR
Analyst ratings (Buy, Hold, Sell) for STAAR stock.
Bulls say / Bears say
First quarter 2025 net sales excluding China grew 9% year-over-year to $42.2 million, reflecting robust demand in non-China markets (Business Wire).
In the second quarter of fiscal 2025, net sales excluding China rose 10% year-over-year to $39.0 million, demonstrating resilience in international markets despite China headwinds (Reuters).
Gross margin improved sequentially in Q2 FY 2025 to 74.0% from 65.8% in Q1 FY 2025, indicating enhanced manufacturing efficiency and cost management (Reuters).
First quarter 2025 net sales plunged 45% year-over-year to $42.6 million due to intentional reduction of channel inventory in China, underscoring persistent China demand challenges (Business Wire).
Second quarter FY 2025 net sales fell 55% year-over-year to $44.3 million, driven by a planned reduction of channel inventory in China, highlighting continued reliance on the Chinese market (Reuters).
STAAR reported a net loss of $54.2 million in Q1 2025 compared with a $3.3 million loss a year earlier, reflecting heavy restructuring charges and operational disruptions (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
STAAR Financial Performance
Revenues and expenses
STAAR Earnings Performance
Company profitability
STAAR News
AllArticlesVideos
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon
Business Wire2 days ago
Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR
Business Wire5 days ago
STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for STAAR stock?
STAAR (STAA) has a market cap of $1.3B as of October 05, 2025.
What is the P/E ratio for STAAR stock?
The price to earnings (P/E) ratio for STAAR (STAA) stock is 0 as of October 05, 2025.
Does STAAR stock pay dividends?
No, STAAR (STAA) stock does not pay dividends to its shareholders as of October 05, 2025.
When is the next STAAR dividend payment date?
STAAR (STAA) stock does not pay dividends to its shareholders.
What is the beta indicator for STAAR?
STAAR (STAA) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.